BioMarin Pharma (BMRN) Tops Q2 EPS by 8c, Affirms FY Revenue Guidance, Lowers R&D Expense Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $126 at SunTrust Robinson Humphrey
August 3, 2018 2:32 PM EDTSunTrust Robinson Humphrey raised its price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $126.00 (from $121.00) while maintaining a Buy rating.
Analyst Edward Nash commented, "BioMarin reported a strong 2nd quarter. All but Kuvan's net product sales beat Street consensus. Prior guidance... More
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $109 at Stifel
August 3, 2018 9:36 AM EDTStifel raised its price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $109.00 (from $102.00) while maintaining a Buy rating.
... MoreBioMarin Pharmaceutical Inc. (BMRN) PT Raised to $98 at Barclays
August 3, 2018 5:06 AM EDTBarclays raised its price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $98.00 (from $95.00) while maintaining a Equalweight rating.
... More